Submitted by Armen Hareyan on Apr 17th, 2008
Emisphere Technologies announced that additional preclinical in vivo studies using dogs further demonstrate that its proprietary eligen technology enhances the absorption of oral B12. These data confirm in a second species Emisphere's earlier-reported proof of concept studies conducted in rats.
"These additional animal studies are an important milestone in our plans to commercialize our eligen technology," said Michael V. Novinski, President and Chief Executive Officer of Emisphere. "Developing a B12 formulation with greater bioavailability will alleviate a significant unmet medical need."
There are currently some five million people in the United States receiving 40 million B12 injections annually to treat a variety of debilitating medical conditions; at least an additional five million people are consuming over 600 million tablets of B12 of various strengths annually.
Source:
Emisphere Technologies, Inc. 